Continuum (Minneap Minn). 2022 Oct 1;28(5):1409-1434. doi: 10.1212/CON.0000000000001180.
Neurodegenerative cerebellar ataxia is a diverse collection of diseases that are unified by gait and balance abnormalities, appendicular incoordination, and abnormalities of eye movement and speech. The differential diagnosis is broad, ranging from paraneoplastic syndromes that progress quite rapidly to unidentified genetic disorders that progress slowly over the course of decades. This article highlights the diagnostic process, including the differential diagnosis, as well as treatment approaches and symptomatic management. The pillars of treatment are physical, occupational, and speech therapy as well as counseling and discussions of disease prognosis, genetics, and reproductive choices. There are many ways to help patients with neurodegenerative cerebellar ataxia and improve their quality of life.
Recent years have seen significant improvements in genetic testing, with reductions in cost of both Sanger sequencing and whole exome sequencing and increasing availability of the latter. These improvements increase clinicians' ability to identify the etiology of neurodegenerative cerebellar ataxia and suggest future treatments. Although no medication has been approved by the US Food and Drug Administration (FDA) for treatment of cerebellar ataxia, research and clinical trials for these diseases are increasing.
Neurodegenerative cerebellar ataxia is characterized by dysarthria, dysmetria, oculomotor abnormalities, and ataxic gait. It has a broad differential diagnosis, and numerous options exist for managing symptoms. Although no medications have been approved specifically for cerebellar ataxia, treatment options are available to improve patients' quality of life.
神经退行性小脑共济失调是一组疾病,这些疾病以步态和平衡异常、四肢协调性差、眼球运动和言语异常为特征。其鉴别诊断范围广泛,从进展迅速的副肿瘤综合征到数十年缓慢进展的未明遗传性疾病。本文重点介绍了诊断过程,包括鉴别诊断,以及治疗方法和症状管理。治疗的支柱是物理、职业和言语治疗,以及疾病预后、遗传学和生殖选择方面的咨询和讨论。有许多方法可以帮助神经退行性小脑共济失调患者并提高他们的生活质量。
近年来,遗传检测取得了显著进展,桑格测序和外显子组测序的成本降低,后者的可用性增加。这些改进提高了临床医生识别神经退行性小脑共济失调病因的能力,并提示了未来的治疗方法。尽管美国食品和药物管理局(FDA)尚未批准任何药物用于治疗小脑共济失调,但针对这些疾病的研究和临床试验正在增加。
神经退行性小脑共济失调的特征是构音障碍、运动失调、眼球运动异常和共济失调步态。其鉴别诊断广泛,有许多管理症状的选择。虽然尚未专门批准用于小脑共济失调的药物,但有治疗选择可改善患者的生活质量。